GLPG VS AMN Stock Comparison
Performance
GLPG75/100
75/100
GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.
AMN10/100
10/100
AMN returned -45.02% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
GLPG78/100
78/100
8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.
AMN84/100
84/100
8 analysts offer 12-month price targets for AMN. Together, they have an average target of 148, the most optimistic target put AMN at 175 within 12-months and the most pessimistic has AMN at 121.
Technicals
GLPG71/100
71/100
GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
AMN36/100
36/100
AMN receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
Earnings
GLPG10/100
10/100
GLPG has missed earnings 10 times in the last 20 quarters.
AMN100/100
100/100
AMN has missed earnings 0 times in the last 20 quarters.
Profit
GLPG40/100
40/100
Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.
AMN76/100
76/100
Out of the last 20 quarters, AMN has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
GLPG50/100
50/100
GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
AMN38/100
38/100
AMN has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Galapagos NV Summary
Nasdaq / GLPG
Healthcare
Biotechnology
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
AMN Healthcare Services Summary
New York Stock Exchange / AMN
Healthcare
Medical - Care Facilities
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, telehealth, credentialing, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including American Mobile, Nursefinders, NurseChoice, HealthSource Global Staffing, Onward Healthcare, O'Grady Peyton International, Med Travelers, Club Staffing, Staff Care, B.E. Smith, and Merritt Hawkins, as well as AMN Revenue Cycle Solutions and AMN Language Services. The company was founded in 1985 and is based in Dallas, Texas.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare GLPG to other companies in the same or a similar industry.